FDA Ducks Fake Drug Dealer Mallard with Decade-Long Ban
Published Date: 5/29/2025
Notice
Summary
Carlton Reico Mallard Jr. is banned for 10 years from importing any drugs into the U.S. because he was convicted of serious crimes involving fake and illegal drugs. He didn’t ask for a hearing, so the ban starts officially on February 23, 2025. This means no drug imports from him for a decade, protecting consumers and keeping things honest.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Ten-Year Drug-Import Ban for Individual
Carlton Reico Mallard Jr. is banned for 10 years from importing or offering for import any drug into the United States, effective February 23, 2025. The FDA based the ban on his federal felony convictions for introducing a misbranded drug with intent to defraud and for illegal importation; he did not request a hearing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-09649, Michael Dominic Diaz: Final Debarment Order
Michael Dominic Diaz is banned for 5 years from bringing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He had a chance to fight this but didn’t respond, so the ban is official starting May 16, 2024. This means no drug imports from him for half a decade, keeping the drug supply safer.
Next: 2025-09652, Quality Poultry and Seafood, Incorporated: Final Debarment Order
Quality Poultry and Seafood, Incorporated (QPS) is banned for 5 years from bringing food into the U.S. because they broke the law. They had a chance to speak up but didn’t, so the ban is official starting March 15, 2025. This means QPS can’t import food, which could impact their business and food supply chains.